ASO VISUAL ABSTRACT

ASO Visual Abstract: Surgical Axillary Staging Before Neoadjuvant Chemotherapy: Who Gets It and Why We Should Avoid It

Kathleen Iles, MD¹, Paula D. Strassle, PhD, MSPH², Chris B. Agala, PhD¹, Julia Button, MD¹, and Stephanie Downs-Canner, MD³

¹Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC; ²Division of Intramural Research, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health, Bethesda, MD; ³Department of Surgical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC

As discussed in our article (<https://doi.org/10.1245/s10434-021-10628-4>), despite level 1 evidence supporting post-neoadjuvant chemotherapy axillary staging for node-negative patients, more than 30% of women between 2013

and 2017 received pre-neoadjuvant chemotherapy surgical staging. As expected, higher rates of axillary lymph node dissection were observed in this cohort.